ATE260263T1 - Heteroaromatische bizyklische verbindungen mit antikrebswirkung - Google Patents

Heteroaromatische bizyklische verbindungen mit antikrebswirkung

Info

Publication number
ATE260263T1
ATE260263T1 AT99310574T AT99310574T ATE260263T1 AT E260263 T1 ATE260263 T1 AT E260263T1 AT 99310574 T AT99310574 T AT 99310574T AT 99310574 T AT99310574 T AT 99310574T AT E260263 T1 ATE260263 T1 AT E260263T1
Authority
AT
Austria
Prior art keywords
compounds
bizyclic
heteroaromatic
formula
cancer effect
Prior art date
Application number
AT99310574T
Other languages
English (en)
Inventor
John Charles Kath
Norma Jacqueline Tom
Eric David Cox
Samit Kumar Bhattacharya
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE260263T1 publication Critical patent/ATE260263T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99310574T 1999-01-27 1999-12-24 Heteroaromatische bizyklische verbindungen mit antikrebswirkung ATE260263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11734199P 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
ATE260263T1 true ATE260263T1 (de) 2004-03-15

Family

ID=22372363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99310574T ATE260263T1 (de) 1999-01-27 1999-12-24 Heteroaromatische bizyklische verbindungen mit antikrebswirkung

Country Status (11)

Country Link
US (2) US6465449B1 (de)
EP (1) EP1029853B1 (de)
JP (1) JP3270834B2 (de)
AT (1) ATE260263T1 (de)
BR (1) BR9906013A (de)
CA (1) CA2290918C (de)
DE (1) DE69915027T2 (de)
DK (1) DK1029853T3 (de)
ES (1) ES2214820T3 (de)
MX (1) MXPA00000174A (de)
PT (1) PT1029853E (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
EE200200710A (et) * 2000-06-22 2004-06-15 Pfizer Products Inc. Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks
BR0113056A (pt) 2000-08-09 2003-07-08 Astrazeneca Ab Composto, processo papa a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, e, uso de um composto
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
US20030125344A1 (en) * 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
US20030087919A1 (en) * 2001-03-23 2003-05-08 Bayer Corporation Rho-kinase inhibitors
DE60212487T2 (de) * 2001-04-13 2006-12-21 Pfizer Products Inc., Groton Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
HUP0501069A2 (en) * 2001-12-12 2006-06-28 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
AU2002357621A1 (en) 2001-12-19 2003-06-30 Ube Industries, Ltd. Process for producing quinazolin-4-one and derivative thereof
CN101607958A (zh) 2002-02-01 2009-12-23 阿斯特拉曾尼卡有限公司 喹唑啉化合物
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
MXPA05006676A (es) * 2002-12-19 2005-08-16 Pfizer Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso.
EP1604665B1 (de) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase-hemmer
EP1636195A1 (de) * 2003-05-27 2006-03-22 Pfizer Products Inc. Chinazoline und pyrido[3,4-d]pyrimidine als rezeptor tyrosin kinase inhibitoren
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7687627B2 (en) * 2003-09-08 2010-03-30 Wockhardt Limited Substituted piperidino phenyloxazolidinones having antimicrobial activity with improved in vivo efficacy
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
MXPA06013996A (es) * 2004-06-02 2007-02-08 Takeda Pharmaceutical Compuesto heterociclico fusionado.
ATE485300T1 (de) 2004-07-16 2010-11-15 Sunesis Pharmaceuticals Inc Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
CA2578075A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
PT1784396E (pt) * 2004-08-26 2011-01-27 Pfizer Compostos amino-heteroarílicos substituídos com pirazole como inibidores de proteína quinases
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
WO2006090261A1 (en) * 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
EP1863848A4 (de) 2005-03-31 2009-09-23 Agensys Inc An 161p2f10b-proteine bindende antikörper und verwandte moleküle
EP1877444A2 (de) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin-antikörper
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
EP1928843A1 (de) * 2005-08-22 2008-06-11 Amgen, Inc Bis-arylharnstoffverbindungen zur behandlung von durch proteinkinase vemittelten krankheiten
EA201300320A1 (ru) 2005-09-07 2014-02-28 Эмджен Фримонт Инк. Моноклональные антитела человека к киназе-1, подобной рецептору активина
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US10357184B2 (en) 2012-06-21 2019-07-23 Globus Medical, Inc. Surgical tool systems and method
US10653497B2 (en) 2006-02-16 2020-05-19 Globus Medical, Inc. Surgical tool systems and methods
US10893912B2 (en) 2006-02-16 2021-01-19 Globus Medical Inc. Surgical tool systems and methods
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
CA2651629A1 (en) 2006-05-09 2007-11-22 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
WO2008009077A2 (en) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US8236823B2 (en) * 2006-10-27 2012-08-07 Amgen Inc. Multi-cyclic compounds and methods of use
CA2671585A1 (en) * 2006-12-22 2008-07-03 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
US8715665B2 (en) 2007-04-13 2014-05-06 The General Hospital Corporation Methods for treating cancer resistant to ErbB therapeutics
US20100255004A1 (en) * 2007-04-13 2010-10-07 Dana Farber Cancer Institute Receptor tyrosine kinase profiling
WO2009033094A2 (en) 2007-09-07 2009-03-12 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
US8211911B2 (en) * 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
AR073501A1 (es) 2008-09-08 2010-11-10 Boehringer Ingelheim Int Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (de) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In-situ-verfahren zur überwachung des emt-status von tumorzellen in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (de) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Verfahren zur identifizierung von mesenchymähnlichen tumorzellen oder deren bildung hemmenden stoffen
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2473500A2 (de) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazolderivate
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3536708A1 (de) 2011-04-19 2019-09-11 Pfizer Inc Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
EP2758402B9 (de) 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidin-und purinderivate
US20140286959A1 (en) 2011-11-08 2014-09-25 Pfizer Inc. Methods of Treating Inflammatory Disorders Using Anti-M-CSF Antibodies
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US11607149B2 (en) 2012-06-21 2023-03-21 Globus Medical Inc. Surgical tool systems and method
US10350013B2 (en) 2012-06-21 2019-07-16 Globus Medical, Inc. Surgical tool systems and methods
JP2015528713A (ja) 2012-06-21 2015-10-01 グローバス メディカル インコーポレイティッド 手術ロボットプラットフォーム
US11395706B2 (en) 2012-06-21 2022-07-26 Globus Medical Inc. Surgical robot platform
US10136954B2 (en) 2012-06-21 2018-11-27 Globus Medical, Inc. Surgical tool systems and method
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
EP2956138B1 (de) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutische verbindungen und verwendungen davon
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX355330B (es) 2013-11-01 2018-04-16 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapeuticos y sus usos.
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
AP2016009530A0 (en) 2014-04-30 2016-10-31 Pfizer Cycloalkyl-linked diheterocycle derivatives
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
KR102139496B1 (ko) * 2014-12-15 2020-07-30 더 리젠츠 오브 더 유니버시티 오브 미시간 Egfr 및 pi3k의 소분자 억제제
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US20180371551A1 (en) 2015-12-03 2018-12-27 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
EP3241518B1 (de) 2016-04-11 2024-10-23 Globus Medical, Inc Systeme für chirurgische werkzeuge
EP3509423A4 (de) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. Kristalline formen von therapeutischen verbindungen und verwendungen davon
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP2019533641A (ja) 2016-09-08 2019-11-21 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態およびその使用
US11427578B1 (en) 2017-07-18 2022-08-30 Bayer Pharma Aktiengesellschaft Substituted pyrrolopyridine-derivatives
CN113382986A (zh) 2018-09-25 2021-09-10 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
WO2020120257A1 (en) 2018-12-11 2020-06-18 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021249913A1 (en) 2020-06-09 2021-12-16 Bayer Aktiengesellschaft 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer
EP4267554A1 (de) 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituierte aminobenzylheteroarylverbindungen als egfr- und/oder pi3k-hemmer
EP4288437A1 (de) 2021-02-05 2023-12-13 Bayer Aktiengesellschaft Map4k1-inhibitoren
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034393A (en) 1989-07-27 1991-07-23 Dowelanco Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
HUT66969A (en) 1991-10-09 1995-01-30 Syntex Inc Benzo- and pyrido-pyridazinone- and pyridazin-thion derivatives, pharmaceutical compositions containing the same and process for the production of thereof
US5283242A (en) 1991-10-24 1994-02-01 American Home Products Corporation Substituted benzimidazoles and quinazolines as antihypertensives
US5256781A (en) 1991-10-24 1993-10-26 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DK40192D0 (da) 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
CZ288955B6 (cs) 1994-02-23 2001-10-17 Pfizer Inc. Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AU704544B2 (en) 1995-03-14 1999-04-29 Novartis Ag Trisubstituted phenyl derivatives
EP3103799B1 (de) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Chinazolinderivate
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
SK72996A3 (en) 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DE19608588A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608653A1 (de) * 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
IL126351A0 (en) * 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
DK0912559T3 (da) * 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DK0882717T3 (da) * 1996-10-01 2010-12-13 Kyowa Hakko Kirin Co Ltd Nitrogenholdige heterocykliske forbindelser
EP0837063A1 (de) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
US8727415B2 (en) * 2011-06-30 2014-05-20 Lund Motion Products, Inc. Vehicle bed extender

Also Published As

Publication number Publication date
US6465449B1 (en) 2002-10-15
EP1029853B1 (de) 2004-02-25
DK1029853T3 (da) 2004-05-24
CA2290918A1 (en) 2000-07-27
EP1029853A1 (de) 2000-08-23
US6867201B2 (en) 2005-03-15
MXPA00000174A (es) 2005-06-30
BR9906013A (pt) 2000-09-05
ES2214820T3 (es) 2004-09-16
JP3270834B2 (ja) 2002-04-02
PT1029853E (pt) 2004-05-31
JP2000309577A (ja) 2000-11-07
CA2290918C (en) 2004-02-17
US20030055049A1 (en) 2003-03-20
DE69915027T2 (de) 2004-12-09
DE69915027D1 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
ATE260263T1 (de) Heteroaromatische bizyklische verbindungen mit antikrebswirkung
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
WO2001098277A3 (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
BG104998A (en) Isothiazole derivatives useful as anticancer agents
PT928788E (pt) Compostos farmaceuticamente activos
ATE289602T1 (de) Quinolin-2-on-derivate verwendbar als antikrebsmittel
IS2293B (is) Arýl sambrædd asapólýsýklísk efnasambönd
ES2168581T3 (es) Derivados de indazol sustituidos.
PT992509E (pt) Novos derivados macrolidos
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA99003849A (es) Derivados 9a, 11b-deshidro de 9-oxima-3-ceto-6-0-metileritromicina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1029853

Country of ref document: EP

REN Ceased due to non-payment of the annual fee